Brief: Acurx Pharmaceuticals Reports Fourth Quarter Results
Acurx Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Acurx Pharmaceuticals To Discuss Fourth Quarter And Full Year 2022 Financial Results And Provide Business Update
Acurx Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Acurx Pharmaceuticals Inc Reports Third Quarter 2022 Results And Provides Business Update
Brief: Acurx Pharmaceuticals Reports Q2 Loss Per Share Of $0.26
Brief: Acurx Announces New Data Presentations From Ongoing Ph2 Clinical Trial Program Of Ibezapolstat For Cdi At The 16Th Biennial Congress Of The Anaerobe Society Of America
Brief: Acurx Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Mln
Brief: Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results And Provides Business Update
Brief: Acurx Pharmaceuticals Reports Q4, Full Year 2021 Results And Provides Business Update
Brief: Acurx Announces Publication Of Positive Phase 2a Clinical Trial Results Of Ibezapolstat For CDI In Clinical Infectious Diseases
Brief: Acurx Announces First Patient Enrolled In Phase 2b Clinical Trial Of Its Lead Antibiotic For Treatment Of Clostridioides Difficile Infection
Brief: Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results And Provides Business Update
Brief: Acurx Announces New Data From Phase 2A Clinical Trial Of C. Difficile Treatment
Brief: Acurx Presents Positive Ibezapolstat Microbiome Data From Its Phase 2A Trial At IDWeek
Brief: Acurx Pharmaceuticals Reports Q2 Loss Per Share Of $0.57
Brief: Health Holland Awards Innovative Research Grant For DNA Pol IIIC Inhibitors To Leiden University Medical Center
Acurx rises on filing patent application for bacterial infection therapy
Brief: Acurx Announces Filing Of Provisional Patent Application For Ibezapolstat To Treat Cdi